KOSDAQChemicals317330

Duksan Techopia

₩8,130 0.00%2026-11-18 close
Market Cap
₩166.5B
Turnover
₩200M
Volume
30K
Shares out.
20.5M
PER
—
PBR
2.5×
EPS
-₩4,230
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Grows, Operating Losses Persist: A Turnaround Test

Duksan Techopia's revenue is rising on semiconductor materials and North American electrolyte sales, but operating losses have continued from the first quarter through the third quarter of 2026, so the timing of a return to profit is the key item to watch.

  1. 1

    Revenue in 2025 was KRW 112.1 billion, up 12.4% year on year, but the operating loss widened to KRW 43 billion and the operating margin was -38.4%.

  2. 2

    Third-quarter 2026 revenue reached KRW 51.8 billion, rising for three straight quarters and up 72.4% from a year earlier, while the operating loss stood at KRW 11.2 billion.

  3. 3

    Press reports from May 2026 said subsidiary Duksan Electera's first-quarter 2026 revenue rose to about KRW 7.8 billion from KRW 0.4 billion a year earlier.

  4. 4

    Total liabilities at the end of 2025 were KRW 540.2 billion, well above total equity of KRW 106.5 billion, and the debt-to-equity ratio was 507.4%.

  5. 5

    Valuation gains and losses on redeemable convertible preferred share derivatives have become a major driver of the net loss, and a valuation loss of about KRW 5.3 billion was disclosed on November 13, 2026.

02

Business structure

Duksan Techopia was founded in 2006 and listed on KOSDAQ in 2019. It is a materials company whose core business is semiconductor and display materials, with secondary battery materials and pharmaceutical intermediates as growth businesses.

SK Securities' April 2026 report estimated the 2025 sales mix at roughly 50% semiconductors, 35% OLED, 6% secondary batteries, 5% pharmaceuticals and 4% other.

The flagship semiconductor product is HCDS (hexachlorodisilane), supplied to Samsung Electronics' 3D NAND process, where the company is cited as holding a 60–70% share. The OLED business supplies organic materials, and recovering share at existing customers is cited as a growth factor.

The battery business sits in subsidiary Duksan Electera, which produces electrolyte at a plant in Tennessee, USA. The company has said the plant could expand to up to 200,000 tons through added capacity.

The pharmaceutical business supplies intermediates for drugs in diabetes, MASH and anticancer treatments to global CDMO clients, and a GMP No. 2 plant with an investment of KRW 26 billion was reported as scheduled for completion in December 2026. Key customers include Samsung Electronics, Samsung Display and SK On.

On competition, the company is cited as the top supplier of HCDS to Samsung Electronics, and it has said it has begun building a North American supply system for electrolyte.

Batteries and pharmaceuticals together were an estimated low-double-digit share of 2025 sales, so new businesses remain small relative to the core.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩30.1B-₩14.9B−49.4%
2025Q4₩28.8B-₩9.7B−33.7%
2026Q1₩39.1B-₩10.4B−26.5%
2026Q2₩42.2B-₩10.6B−25.0%
2026Q3₩51.8B-₩11.2B−21.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩111B₩9.3B₩16.1B8.3%8.5%46.9%
2023₩94.1B-₩6.2B-₩7.4B−6.6%−4.2%179.1%
2024₩99.7B-₩30.2B-₩53.1B−30.3%−26.8%222.2%
2025₩112.1B-₩43B-₩76.7B−38.4%−66.6%507.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 111 billion in 2022 to KRW 94.1 billion in 2023 (down 15.3% year on year), then rose to KRW 99.7 billion in 2024 (up 6.0%) and KRW 112.1 billion in 2025 (up 12.4%), marking two straight years of growth. Among 2022–2025, 2025 was the largest year and 2023 the smallest.

Operating profit of KRW 9.26 billion in 2022 turned into an operating loss of KRW 6.23 billion in 2023, then widened to an operating loss of KRW 30.2 billion in 2024 and KRW 43 billion in 2025.

The operating margin moved from 8.3% in 2022 to -6.6% in 2023, -30.3% in 2024 and -38.4% in 2025, and the company has recorded losses in each of the three years from 2023 to 2025. The 2025 widening was attributed by the company to depreciation and ramp-up costs at the North American plant of subsidiary Duksan Electera.

Net loss attributable to controlling shareholders went from net income of KRW 16.1 billion in 2022 to net losses of KRW 7.4 billion in 2023, KRW 53.1 billion in 2024 and KRW 76.7 billion in 2025.

Net loss including non-controlling interests was KRW 105.6 billion in 2025, a larger figure, with the main difference being about KRW 57.4 billion of non-cash derivative valuation costs on redeemable convertible preferred shares, which the company said involve no cash outflow.

Operating cash flow went from KRW 12.3 billion in 2022 to negative figures of KRW 7.83 billion in 2023, KRW 56.2 billion in 2024 and KRW 21.4 billion in 2025.

Quarterly revenue went from KRW 30.1 billion in the third quarter of 2025 and KRW 28.8 billion in the fourth quarter (down 4.1% quarter on quarter) to KRW 39.1 billion, KRW 42.2 billion and KRW 51.8 billion in the first three quarters of 2026, rising for three consecutive quarters.

Over the same span the operating loss was KRW 14.9 billion, KRW 9.72 billion, KRW 10.4 billion, KRW 10.6 billion and KRW 11.2 billion, extending five straight loss-making quarters.

Press reports in May 2026 said the first-quarter 2026 separate-basis operating profit turned positive at KRW 0.9 billion, while the consolidated figure was a loss.

The net loss attributable to controlling shareholders for the last four quarters totaled KRW 86.4 billion, and whether revenue growth narrows the operating loss is the point to check in upcoming quarters.

05

Industry analysis

In semiconductors, April 2026 brokerage reports share a common view that AI data center investment is lifting SSD and NAND demand, and that higher NAND layer counts increase the number of ALD steps and therefore HCDS usage.

A second brokerage report noted that most of the company's semiconductor materials sales are tied to NAND, which it cited as the basis for structural growth. That is a forecast by analysts, however, and with semiconductors around half of 2025 sales, results are closely linked to the NAND investment cycle.

In OLED, recovering share at existing customers and profitability gains from process improvements are cited. In batteries, US energy storage demand and North American local production under the Inflation Reduction Act are the cited growth drivers.

Because electrolyte must be produced locally in North America, early operators are seen as advantaged, but whether utilization and customer wins translate into profit is the open question.

Among chemical sector peers, commodity petrochemical companies such as LG Chem, Lotte Chemical and Kumho Petrochemical are driven by feedstock and price cycles, whereas Duksan Techopia's demand tracks semiconductor and display materials, so its cycle differs.

In electrolyte, the company competes with domestic peers such as Foosung in North American local production. Its position in semiconductor precursors is strong, but the new businesses do not yet contribute to profit, so industry conditions and company-level earnings gaps need to be read together.

06

Outlook

In its March 2026 results briefing, the company described 2026 as the first year of an earnings turnaround, citing the full operation of the North American electrolyte plant and rising semiconductor materials demand tied to AI.

A second brokerage's April 2026 report projected a 2026 operating profit of KRW 13.7 billion after a turn from loss, on revenue of KRW 236.2 billion. SK Securities' April 2026 report estimated battery-segment sales rising from KRW 6.3 billion in 2025 to KRW 127.1 billion in 2026 and KRW 263.2 billion in 2027.

Both estimates date from April 2026, and reported quarterly operating losses in the first three quarters of 2026 mean the gap between those forecasts and actual results is what to check.

On new capacity, the GMP No. 2 plant with an investment of KRW 26 billion was reported as scheduled for completion in December 2026, with K-GMP certification expected in the first half of 2027 before full-scale production.

The same report estimated combined capacity of the first and second plants at about KRW 160 billion and projected profit contribution from 2027 after break-even in 2026. In semiconductors, the axes of the outlook are rising HCDS demand from higher-layer 3D NAND at Samsung Electronics and share recovery in OLED.

On the balance sheet, the company said in March 2026 that conversion of the redeemable convertible preferred shares into common stock would move the derivative valuation loss into equity and improve capital structure.

A valuation loss of about KRW 5.3 billion on those derivatives was disclosed on November 13, 2026, and the company stated it involves no cash outflow.

The next checkpoints are the operating profit sign and fourth-quarter loss in the 2026 annual report, and how quickly pharmaceutical sales are recognized after the GMP No. 2 plant opens.

07

Valuation

PER
—
PBR
2.5×
ROE
-72.8%
EPS
-₩4,230
BPS
₩3,594
Dividend per share
₩0

Because the company has posted net losses attributable to controlling shareholders over the last four quarters, its price-to-earnings ratio cannot be calculated. Comparisons therefore rest on asset-based multiples.

The price-to-book ratio sits above 1 times and, in the quarter-end series compiled by FnGuide from June 2024 to June 2025 (roughly from the low 1x range to the low 4x range), it lies in the middle part of that band. That band reflects past quarter-end data and should be read apart from the current share price.

No dividend was paid over the periods checked, so dividends provide no support to the share price. Total liabilities of KRW 540.2 billion against total equity of KRW 106.5 billion at the end of 2025 weigh on how an asset-based multiple should be read.

The turnaround to profit projected in April 2026 has not yet appeared in reported results, so an earnings-based multiple would become calculable only after profitable quarters accumulate.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Semiconductor share and NAND demand

SK Securities' April 2026 report put the company's HCDS share within Samsung Electronics' 3D NAND process at 60–70%. Three straight quarters of revenue growth suggest the core business is supporting sales. Third-quarter 2026 revenue was KRW 51.8 billion, up 72.4% from a year earlier. Analysts argue AI data center investment is raising NAND demand and HCDS usage as layer counts rise.

Rapid growth in North American electrolyte sales

Press reports from May 2026 said subsidiary Duksan Electera's first-quarter 2026 revenue reached about KRW 7.8 billion, up from KRW 0.4 billion a year earlier. The reports noted that one quarter exceeded the subsidiary's full-year 2025 electrolyte sales.

The company has said the Tennessee plant can expand to as much as 200,000 tons. A brokerage has also estimated battery sales rising from KRW 6.3 billion in 2025 to KRW 127.1 billion in 2026.

Expansion of pharmaceutical intermediate capacity

The pharmaceutical intermediate business has a GMP No. 2 plant with an investment of KRW 26 billion that was reported as scheduled for completion in December 2026. That report gave a target annual revenue of about KRW 160 billion after completion.

The segment supplies intermediates for diabetes, MASH and anticancer treatments to global CDMO clients. How far new businesses change the sales mix depends on how fast revenue is recognized after completion.

09

Bear factors

Persistent and widening operating losses

The 2025 operating loss widened to KRW 43 billion from KRW 30.2 billion in 2024, and the operating margin was -38.4%. Quarterly operating losses of KRW 10.4 billion, KRW 10.6 billion and KRW 11.2 billion in the first three quarters of 2026 show that revenue growth has not narrowed losses much.

Losses have been recorded for three straight years from 2023, and reported results show five straight loss quarters. The profit turn projected by brokerages in April 2026 has not yet appeared in reported results.

Balance sheet pressure

Total liabilities at the end of 2025 were KRW 540.2 billion, well above total equity of KRW 106.5 billion, and the debt-to-equity ratio rose from 46.9% in 2022 to 507.4% in 2025. Operating cash flow has been negative for three years since 2023, reaching KRW -21.4 billion in 2025.

An October 2025 report noted that the interest coverage ratio had been below 1 for three years. Further capital spending while borrowing costs are high could further reduce financial room.

Volatility from derivative valuation

The 2025 net loss including non-controlling interests of KRW 105.6 billion was larger than the controlling-shareholder net loss of KRW 76.7 billion, mainly because of about KRW 57.4 billion in derivative valuation costs on redeemable convertible preferred shares. The company said this cost involves no cash outflow.

A valuation loss of about KRW 5.3 billion disclosed on November 13, 2026 shows the same item still affects reported earnings. Because the cost rises as the subsidiary's valuation rises, net income swings are large.

10

Risk factors

Electrolyte ramp-up and utilization

Even as North American electrolyte sales ramp up, the timing of break-even is seen as the key to consolidated earnings improvement. Depreciation and early operating costs can keep operating losses in place even as revenue grows.

Losses continuing from the first quarter through the third quarter of 2026 show this pattern. If customer wins and utilization are delayed, the recovery of capital spending slows.

Customer concentration and industry dependence

Major customers include Samsung Electronics, Samsung Display and SK On, so the company depends heavily on a few clients and on their industry conditions. Semiconductors were estimated at around half of 2025 sales, and HCDS demand depends on the pace of Samsung Electronics' 3D NAND investment.

The OLED outlook assumes share recovery at existing customers. A change in one customer's capital spending could affect revenue directly.

Capital structure and policy variables

With a debt-to-equity ratio of 507.4% at the end of 2025 and redeemable convertible preferred shares still outstanding, the capital and earnings structure could change depending on conversion timing and terms.

The company said conversion into common stock would move the derivative loss into equity and improve the capital structure. The North American electrolyte strategy partly relies on US policy such as the Inflation Reduction Act, so a policy change could alter demand assumptions.

11

What to watch next

  1. December 2026

    Scheduled completion of the GMP No. 2 plant. Whether completion proceeds on schedule and how quickly pharmaceutical sales are recognized afterward are the next items to check.

  2. First half 2027

    Expected timing for K-GMP certification. Reports say full-scale production would follow certification, so certification is a precondition for the pharmaceutical sales outlook.

  3. By end-March 2027

    Deadline for the 2026 annual report. It is the point to check whether annual operating profit turns positive, the size of the fourth-quarter operating loss, and whether the quarterly trend from the first to third quarter of 2026 continues.

  4. By mid-May 2027

    Deadline for the first-quarter 2027 report. It shows whether quarterly growth in North American electrolyte sales narrows operating losses and how much derivative valuation gain or loss is booked.

12

Overall view

Duksan Techopia's revenue is growing, with KRW 112.1 billion in 2025 (up 12.4%) and KRW 51.8 billion in the third quarter of 2026, which marked three straight quarters of growth.

In semiconductor materials, it is cited as holding a 60–70% share of HCDS in Samsung Electronics' 3D NAND process, which provides a base for the core business.

Operating losses widened to KRW 43 billion in 2025, and reported quarterly losses continued from the first through the third quarter of 2026, so a profit turn has not yet appeared in reported results.

On the balance sheet, the debt-to-equity ratio of 507.4% at the end of 2025 and negative operating cash flow remain burdens. Derivative valuation costs on redeemable convertible preferred shares add swings to net income and complicate interpretation.

North American electrolyte and pharmaceutical intermediates have schedules for completion in December 2026 and certification in the first half of 2027, so their results can be judged after those points.

The most direct check is the sign of annual operating profit and the size of the fourth-quarter loss in the 2026 annual report, the next periodic filing.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. zdnet.co.kr
  2. thelec.kr
  3. core.asiae.co.kr
  4. erountv.com
  5. ibtomato.com
  6. view.asiae.co.kr
  7. thelec.kr
  8. eduinfom.com
  9. dailyinvest.kr
  10. theinvest.co.kr
  11. investing.com
  12. sks.co.kr
  13. investing.com
  14. leadingkorea.com
  15. comp.fnguide.com
  16. digitaltoday.co.kr
  17. v.daum.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis